URGANCH DAVLAT TIBBIYOT INSTITUTI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-3. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740
UDC: 616.833.17-009.11-07-08

INTEGRATED NEUROPHYSIOLOGICAL AND DIGITAL FRAMEWORK FOR PERSONALIZED MANAGEMENT OF FACIAL NERVE NEUROPATHY: A COMPREHENSIVE REVIEW

Aripova
Maftuna Khurramovna[1]
ORCID:0009-0007-7910-5575
Email:Maftunaripova@gmail.com



Yokubova Fotima Zokir kizi[2],
ORCID:0009-0006-1900-0176
Email: fotimab97@gmail.com



Abdurazzokova Shakhlo Ilkhom kizi[3]
ORCID:0009-0001-3760-8891
Email: abdurazzakova.shakhlo@gmail.com



[1] *Department of Neurology and Folk Medicine, PhD, Associate professor, Tashkent State Medical University*
[2-3] *Department of Neurology and Folk Medicine, first-year residents of Tashkent State Medical university*
***Corresponding author:** Maftunaripova@gmail.com

Abstract

To substantiate the necessity of a personalized management model for facial nerve neuropathies and to define the integrative roles of neurophysiological assessment, quantitative facial expression analysis, and remote patient monitoring.

A structured review was performed across PubMed/MEDLINE, the Cochrane Library, the Russian Science Citation Index (eLIBRARY.RU), and open-access medical journal archives of Uzbekistan. Publications evaluated included clinical practice guidelines, systematic reviews, observational cohort studies, diagnostic accuracy trials, and digital health validation studies.

The annual population-based incidence of Bell’s palsy ranges from 11 to 40 cases per 100,000 population, with 15–20% of affected individuals suffering long-term sequelae including permanent weakness, synkinesis, or facial contracture. While traditional clinical scales (e.g., House–Brackmann) remain the primary tool for initial severity classification, their discrete grading nature limits sensitivity to minor longitudinal changes. Electroneuromyography (ENMG) provides critical prognostic accuracy when performed between day 3 and the end of the 3rd week post-onset, whereas needle electromyography (EMG) and blink reflex testing offer vital prognostic insights into axonal reinnervation and proximal reflex arc continuity at later stages. In a cohort of 796 patients, early preservation of the R1 blink reflex component predicted House–Brackmann Grade I recovery in 85.0% of cases compared to 57.6% when R1 was absent. Automated facial image analysis correlates with clinical trajectories in 85% of paired evaluations, though external algorithm validation remains scarce. Local epidemiological data from Uzbekistan demonstrate distinct phenotypic variations related to age, vascular comorbidities, and otogenic etiologies, yet routine digital tracking and unified multimodal protocols remain unestablished.

Effective personalization in facial neuropathy requires moving beyond single-point severity scores. A synchronized framework combining etiological screening, standard clinical scales, electrophysiological diagnostics, quantitative digital motion tracking, and patient-reported outcomes must be established and prospectively validated.

Keywords: facial nerve, peripheral facial palsy, Bell’s palsy, electroneuromyography, blink reflex, synkinesis, rehabilitation, quantitative assessment of facial movements, remote follow-up, personalized medicine.

INTRODUCTION

Peripheral facial nerve lesions represent a complex functional, structural, and psychosocial disorder that extends far beyond transient facial asymmetry. A single pathological lesion simultaneously impairs eyelid closure, oral competence during mastication, speech articulation, non-verbal emotional expression, and social interaction. When the lesion is located proximal to the geniculate ganglion or stapedial nerve, autonomic lacrimation, salivation, gustatory function, and acoustic tolerance are compromised. Consequently, identical nominal baseline paresis grades can present vastly different clinical risks; one patient may present predominantly with mild lower facial sagging, while another faces severe lagophthalmos with corneal exposure, agonizing retroauricular pain, or early pathological synkinesis.

Epidemiological studies emphasize the ongoing burden of this condition. Recent population-based data indicate an average annual incidence of Bell’s palsy of approximately 24.5 per 100,000 population, with reported global ranges spanning 11 to 40 per 100,000. Recurrence is observed in 5.9% to 6.5% of individuals. Although a large proportion of patients experience complete spontaneous or corticosteroid-assisted recovery, 15% to 20% develop long-term sequelae including persistent paresis, synkinesis, muscle contracture, gustatory lacrimation ("crocodile tears"), eye irritation, and severe social limitation. Even minor persistent asymmetry can lead to significant psychological distress and occupational impairment, particularly for individuals in public-facing roles.

Systematic reviews assessing the psychosocial impact of facial palsy confirm a marked decrease in health-related quality of life and high rates of anxiety and depression, which do not always correlate linearly with physician-graded physical severity. Investigations evaluating patients with facial nerve disorders and hemifacial spasm report significantly elevated depressive symptoms, social anxiety, alexithymia, and impaired emotional recognition compared to healthy controls. Thus, improvements on a motor assessment scale do not inherently equate to full functional and psychological recovery.

Current clinical guidelines clearly establish acute management: systemic corticosteroids should be administered within 72 hours of onset for typical Bell's palsy, antiviral therapy may be added based on severity and clinical context, and aggressive eye protection is mandatory for compromised eyelid closure. However, a substantial gap exists between acute pharmacotherapy and long-term neuro-rehabilitation. Key clinical questions remain unresolved regarding the exact optimal timing for electroneurography (ENoG), the integration of needle EMG, the criteria for modifying physical exercise regimes, and the most reliable means of tracking clinical progress between infrequent outpatient visits.

Digital health solutions—such as 2D/3D facial tracking, smartphone applications, and remote monitoring—offer potential tools to bridge this gap, but technology alone cannot solve the clinical challenge without proper integration. The primary aim of this review is to formulate a comprehensive, evidence-based, clinical-neurophysiological model for personalized facial nerve neuropathy management, evaluate the validated and controversial aspects of digital technologies, and synthesize international evidence with regional clinical data from Uzbekistan.

MATERIALS AND METHODS

A comprehensive review of literature was conducted utilizing key biomedical databases:

- US National Library of Medicine (PubMed / MEDLINE)
- Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews
- Russian Science Citation Index (eLIBRARY.RU) and Scientific Electronic Library
- Open-access archives of national medical journals of Uzbekistan (e.g., *Integrative Dentistry and Maxillofacial Surgery*, *Journal of Neurology and Neurosurgical Research*, *Doctor Ahborotnomasi*).

Case reports of central facial paresis (e.g., stroke without lower motor neuron facial involvement), cosmetic/aesthetic surgical literature unrelated to nerve injury, unvalidated software technical reports lacking clinical data, and studies with ill-defined sampling methodologies.

For each selected publication, structural variables were extracted: sample size, etiology (idiopathic, otogenic, vascular, herpes zoster), baseline clinical severity, timing of neurophysiological testing, analytical scale utilized, follow-up duration, and functional outcomes. Qualitative risk of bias was assessed by evaluating cohort selection methods, presence of comparison groups, follow-up completeness, and external validation of digital algorithms.

RESULTS

Bell's palsy remains a diagnosis of exclusion rather than a catch-all term for acute peripheral facial weakness. Rapid unilateral onset involving both the upper and lower facial muscles without additional focal neurological deficits strongly points to idiopathic facial neuropathy. However, a thorough diagnostic evaluation of the external auditory canal, parotid gland, hearing acuity, corneal integrity, and adjacent cranial nerves is mandatory. Insidious onset (>72 hours), recurrent ipsilateral weakness, bilateral involvement, vesicular eruptions, severe otalgia, hearing loss, vertigo, multiple cranial neuropathies, or failure to recover within 3–4 weeks necessitate immediate neuroimaging and targeted laboratory testing.

Within idiopathic cohorts, significant heterogeneity exists regarding complete versus incomplete paralysis, neuropathic pathophysiology (neurapraxia vs. axonal degeneration), presentation timing, and systemic comorbidities such as diabetes mellitus, arterial hypertension, and pregnancy. Clinical guidelines recommend selective, risk-adapted diagnostic testing. In resource-conscious healthcare systems, personalization relies on targeted, high-yield investigations rather than exhaustive testing for every patient.

Initial physical severity only partially predicts long-term functional recovery. Incomplete paresis carries a favorable prognosis, whereas complete prosopoplegia increases the likelihood of Wallerian degeneration. Advanced age, diabetes, severe pain, and autonomic deficits increase the risk

of incomplete recovery, but no single clinical feature provides sufficient prognostic precision on its own. Thus, baseline examination establishes a pre-test probability that must be refined over time using electrophysiological and quantitative kinematic data.

The **House–Brackmann (HB) grading scale** remains the global standard for baseline severity classification. However, its 6-point ordinal structure aggregates resting symmetry, voluntary movement, and secondary complications (such as synkinesis and contracture) into single broad categories. Consequently, subtle but clinically meaningful dynamic changes often go undetected. Regional instruments, such as the **Sunnybrook Facial Grading System**, offer higher sensitivity to specific facial zones and secondary synkinesis, but remain subject to intra-observer and inter-observer variability.

Scale System	Primary Evaluation Focus	Key Strengths	Diagnostic Limitations
House–Brackmann (HB)	Global static and dynamic facial impairment (Grades I–VI)	Universally accepted, rapid, simple for routine primary care documentation	Low sensitivity to minor improvements; conflates movement amplitude with synkinesis
Sunnybrook Facial Grading System	Regional assessment (resting symmetry, voluntary movement, synkinesis)	Continuous scoring (0–100), sensitive to regional recovery and synkinesis	Dependent on clinician experience and visual lighting conditions
Automated Digital Kinetic Analysis	Continuous 2D/3D coordinate tracking of key facial landmarks	Objective, highly sensitive to subtle dynamic changes, automated longitudinal tracking	Susceptible to lighting/angle variations; requires external validation across diverse demographics

Observer-dependent limitations have direct therapeutic consequences: a physician may perceive stability, whereas the patient notices enhanced oral fluid retention or, conversely, progressive involuntary eye closure during smiling. Static photography fails to resolve this discrepancy, as a completely motionless, symmetrical face may receive a superior static score compared to a face with high dynamic excursion but mild residual asymmetry. Comprehensive evaluation must therefore capture static geometry, maximal dynamic excursion, movement velocity, holding stability, fatigue, and involuntary synkinetic contraction. A two-tier assessment model is optimal: Tier 1 utilizes validated clinical scales alongside assessments of eye closure, pain, gustation, and speech; Tier 2 incorporates continuous quantitative motion tracking.

Electrophysiological testing requires precise physiological timing. During the first 72 hours following acute nerve injury, the distal nerve segment continues to conduct action potentials despite severe proximal disruption. Consequently, premature ENoG can underestimate future axonal degeneration. The optimal diagnostic window for evaluating compound muscle action potential (CMAP/M-response) amplitude degradation is between **day 3 and the end of the 3rd week** post-

onset. Beyond day 21, initial prognostic yield from ENoG declines, whereas needle EMG gains utility by detecting fibrillation potentials (confirming denervation) or early polyphasic motor unit action potentials (MUAPs, signaling axonal reinnervation).

Clinical guidelines recommend nerve conduction studies for severe paresis, ideally performed between **days 9 and 20** post-onset, when Wallerian degeneration is complete but long-term outcomes remain modifiable. Standard ENoG protocols must be side-to-side and reproducible, comparing side-to-side side CMAP amplitudes using standardized electrode placement and supramaximal stimulation. Surveys of clinical practice show that some neurologists perform un-stimulated or unilateral testing, an approach that degrades prognostic utility by preventing intra-individual comparisons.

A study of 193 patients combining ENoG degeneration index, CMAP latency, blink reflex testing, nerve excitability thresholds, and needle EMG demonstrated superior predictive power compared to single-parameter testing. In severe presentations, interference pattern analysis on needle EMG and side-to-side thresholds provided critical sub-stratification.

Practice surveys reveal gaps between evidence-based recommendations and routine care. A survey of 172 practicing neurologists found that while 95.9% utilized detailed verbal descriptions of facial weakness, standardized clinical scales were employed by only 28.5%. Diagnostic stimulation ENMG was ordered by 38.4%, MRI by >70%, and CT by ~25%. Nearly one-third of clinicians omitted basic diagnostic laboratory workups, and while two-thirds referred patients for physical rehabilitation, standardized protocols were lacking. Furthermore, clinicians systematically prioritized upper facial examination (lagophthalmos) while under-evaluating lower facial motor function, hypertonia, and secondary synkinesis.

During the acute phase, early administration of systemic corticosteroids within 72 hours of symptom onset remains the most effective intervention to prevent permanent denervation. Monotherapy with antiviral agents is unsupported by high-level evidence, though combination antiviral-corticosteroid therapy is reasonable in severe presentations or suspected Ramsay Hunt syndrome (herpes zoster oticus). Ramsay Hunt cases—characterized by severe otalgia, painful vesicular lesions, and frequent vestibulocochlear dysfunction—require rapid co-management by neurology and otolaryngology. Eyelid insufficiency and reduced blink frequency pose an immediate threat of corneal drying, ulceration, and permanent keratitis; protective lubrication, nocturnal eye taping, and timely ophthalmology consultations must be instituted regardless of the overall facial score.

Systematic reviews confirm that targeted facial physical therapy improves functional recovery and reduces sequelae, though trial designs vary widely in exercise intensity, timing, and monitoring. Prescribing a static, unvarying exercise routine throughout all recovery phases is physiologically counter productive:

Priority must be placed on gentle movement, preventing muscular overstretching, and avoiding uncoordinated exertion. Focus shifts to biofeedback-assisted, controlled, symmetrical movements with visual or sensory reinforcement. High-intensity motor exertion is contraindicated. Rehabilitation must prioritize slow, isolated, submaximal contractions, relaxation techniques, and suppression of unwanted co-contractions.

For persistent synkinesis and hypertonia, combining localized botulinum toxin type A (BoNT-A) injections with targeted physical therapy provides superior outcomes. In a comparative trial of 146 facial palsy patients, all participants underwent physical rehabilitation, with 38 receiving supplementary BoNT-A injections and 108 continuing specialized exercise alone. This demonstrates how objective neurophysiological severity markers can guide advanced rehabilitation strategies.

Systematic evaluations of 2D and 3D computer vision algorithms reveal rapid advances in automated facial tracking, alongside challenges related to dataset heterogeneity and algorithm validation. Modern algorithms auto-detect dynamic landmarks on the eyebrows, eyelids, nasal bridge,

and lips, calculating dynamic distances, symmetry angles, and movement velocities. Advanced deep-learning frameworks analyze frame sequences to detect micro-synkinesis. Standardized recording environments - consistent lighting, distance, head positioning, and structured motor tasks - are essential for diagnostic accuracy.

In a systematic review of 35 computer-vision studies applied to facial palsy, independent external validation was performed in only 5 studies. Algorithms trained on homogeneous data sets frequently experience degradation in accuracy when exposed to variations in skin tone, age, facial wrinkles, facial hair, ambient lighting, or mobile device cameras. Rigorous local validation is therefore required before deployment in clinical settings.

Tele-rehabilitation models offer practical advantages for patients facing geographical or mobility barriers. Weekly structured video submissions permit remote tracking between scheduled neurophysiological visits. Remote monitoring enables early detection of key complications, including rising pain levels, ocular irritation, or emerging synkinesis, reducing both delayed clinical responses and unnecessary travel.

However, high-level clinical trial evidence remains limited. A scoping review of 39 remote rehabilitation publications identified 14 technical solutions suitable for home monitoring, but clinical implementation was confined to small pilot cohorts, with a lack of randomized controlled trials. Safe digital monitoring applications must incorporate safety algorithms that automatically prompt urgent in-person medical evaluation upon detecting red flag symptoms: secondary neurological deterioration, severe otalgia, vesicular lesions, corneal abrasion, bilateral weakness, or lack of recovery by 4 weeks. Furthermore, encrypted data storage and patient consent protocols are essential when handling sensitive biometric video data.

Large-scale electronic health records (EHR) illustrate both the potential and limitations of epidemiological tracking. An analysis of a metropolitan digital health system covering 95% of the registered population from 2019 to 2021 demonstrated baseline adult annual incidences of 15.5 per 100,000 for idiopathic facial neuropathy and 13.7 per 100,000 for symptomatic forms (pediatric rates were 9.6 and 11.8 per 100,000, respectively). While EHR data effectively captured population-level incidence, unstandardized text entry limited longitudinal outcome tracking. Establishing prospective national registries requires standardized, mandatory data fields prior to registry launch.

Clinical studies conducted across specialized centers in Uzbekistan provide regional data on etiology, neurophysiology, and outcomes:

A clinical study conducted at the Bukhara Multidisciplinary Medical Center evaluated 75 acute facial neuropathy patients (33 men, 42 women; mean age 37.5 and 34.3 years). Subgroup analysis identified 51 idiopathic cases, 12 vascular cases, 7 otogenic cases, and 3 cases of Ramsay Hunt syndrome. Notably, 85% of idiopathic cases (43/51) reported cold exposure as an immediate triggering factor. A separate study from Bukhara examining 163 patients with complicated facial neuropathies (66 men, 97 women; mean age 43 years) established a link between facial contracture, vascular comorbidities, and chronic psychosocial distress.

Methodological reviews published in Uzbekistan emphasize structured diagnostic workups, neuroimaging, and early physical rehabilitation. Additional pediatric reports discuss early therapeutic interventions. However, existing regional studies are predominantly single-center trials. To date, no multi-center prospective study in Uzbekistan has integrated standardized clinical grading, serial ENMG, digital video kinematics, and validated quality-of-life metrics within a single longitudinal cohort.

DISCUSSION

Synthesis of the literature indicates that the primary challenge in facial nerve management is not a lack of individual diagnostic tools, but rather their fragmented clinical application. Clinical scales evaluate visible external asymmetry, electroneurography quantifies intact motor axons during specific diagnostic windows, needle EMG assesses denervation and reinnervation, blink reflex testing

measures reflex arc integrity, digital computer vision captures continuous kinetic trajectories, and patient-reported outcome measures quantify psychosocial burden. Optimal management requires synthesizing these diagnostic modalities into a coordinated continuum.

PHASE 1: ACUTE PRESENTATION
(Days 1 - 3)
* Etiological screening (rule out secondary causes: otogenic, zoster, vascular)
* Eye preservation protocol (lubricants, taping, ophthalmology referral)
* Pharmacotherapy (oral corticosteroids within 72h +/- antivirals)
* Baseline HB / Sunnybrook scoring + initial baseline 2D/3D video capture

PHASE 2: NEUROPHYSIOLOGICAL STRATIFICATION
(Days 4 - 21)
* Side-to-side ENoG testing (Days 9-14 preferred for CMAP decay quantification)
* Blink reflex testing at ~Day 14 (R1 response latency and preservation)
* Risk stratification:
  - High CMAP preservation / R1 present -> Low risk (routine follow-up)
  - >90% CMAP reduction / R1 absent -> High risk (intense monitoring)

PHASE 3: DYNAMIC DIGITAL REHABILITATION
(Weeks 3 - 12)
* Needle EMG (evaluates fibrillation potentials vs. polyphasic MUAP units)
* Stage-adapted biofeedback exercise (avoid hyper-exertion in severe denervation)
* Weekly quantitative smartphone video tracking (monitors speed & symmetry)
* Early detection of emerging synkinesis (oculo-oral / oral-ocular)

PHASE 4: LONG-TERM OUTCOMES & RE-INNERVATION
(Months 3, 6, 12)
* Comprehensive evaluation: HB scale, Sunnybrook scale, FaCE quality of life
* Targeted Botulinum Toxin Type A (BoNT-A) for established synkinesis/contracture
* Surgical / re-animation consultation for complete non-recovery at 12 months

Phase 1: Acute Evaluation (Days 1–3)

The priority during initial presentation is confirming a lower motor neuron etiology, excluding secondary causes, initiating protective corneal care, and administering systemic corticosteroids within the 72-hour window. Clinical severity should be documented using both the House–Brackmann and Sunnybrook scales. Baseline pain, gustatory, lacrimal, and acoustic symptoms must be recorded alongside a standardized short video recording capturing key facial expressions (resting face, eyebrow elevation, gentle and tight eye closure, smiling, lip pursing, and cheek puffing).

Phase 2: Neurophysiological Risk Stratification (Days 4–21)

For patients with complete prosopoplegia or poor prognostic indicators, side-to-side ENoG should be performed between days 9 and 14 post-onset. Blink reflex testing around day 14 provides complementary prognostic information regarding nerve continuity. Patients exhibiting >90% CMAP amplitude reduction alongside an absent R1 response are stratified into a high-risk category requiring intensive follow-up, early needle EMG, and targeted rehabilitation planning.

Phase 3: Dynamic Digital Tracking and Rehabilitation (Weeks 3–12)

As voluntary motor recovery begins, needle EMG helps differentiate active denervation from nascent reinnervation. Physical exercise protocols must be tailored to electrophysiological findings: force-based exercises are avoided in severe denervation to minimize aberrant reinnervation. Automated video motion tracking provides objective tracking between clinic visits. Software algorithms should report sub-scores for regional excursion, velocity, and involuntary co-contractions. If smile amplification triggers progressive involuntary eye narrowing, the system flags emerging synkinesis, prompting a shift toward suppression exercises rather than maximal force generation.

Phase 4: Long-Term Outcome Assessment (Months 3, 6, 12)

Long-term evaluation at 3, 6, and 12 months should combine physician-graded scales (HB and Sunnybrook), automated video kinematics, and validated patient-reported outcome measures (e.g., Facial Clinimetric Evaluation [FaCE] instrument). In cases with established hypertonia or disabling synkinesis, targeted BoNT-A injections integrated with biofeedback physical therapy provide validated functional improvements.

To establish this model in clinical practice - particularly within Uzbekistan - standardized protocols, regional baseline data, and validated digital algorithms are required. Future prospective clinical studies should evaluate this integrated framework to assess its impact on recovery rates, synkinesis prevention, and patient quality of life.

CONCLUSION

Personalized management of facial nerve neuropathy requires an integrated diagnostic approach. Conventional clinical grading scales, while essential for initial screening, lack the sensitivity required to track subtle recovery or detect early synkinesis. Neurophysiological testing (ENoG, needle EMG, and blink reflex) provides key prognostic metrics during defined physiological windows, while modern computer vision and mobile technologies enable objective kinematic tracking.

Integrating clinical risk factors, serial neurophysiology, automated motion analysis, and patient-reported outcomes into a standardized pathway enables individualized treatment selection from tailored physical therapy to targeted botulinum toxin administration. Prospective validation of this multidisciplinary framework within the healthcare system of Uzbekistan represents a logical step toward optimizing patient outcomes.

REFERENCES

1. Wei E.H., Green A., Pepper J.P., Akkina S.R. Rising incidence of facial nerve disorders in the United States from 2007 to 2022. *Laryngoscope*. 2025;135:2008–2013. DOI: 10.1002/lary.31997.
2. Varga E. et al. Epidemiology and recurrence of Bell's palsy. *Frontiers in Neurology*. 2023;14:1188137. DOI: 10.3389/fneur.2023.1188137.
3. Dong S.H. et al. Incidence and outcomes of recurrent Bell's palsy. 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/30672667/
4. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. *Acta Otolaryngologica Supplementum*. 2002;549:4–30.
5. Lee S.A. et al. Clinical practice guidelines for the evaluation and management of facial nerve palsy. *Clinical and Experimental Otorhinolaryngology*. 2026. DOI: 10.21053/ceo.2026-00096.
6. Ministry of Health of the Russian Federation. Cranial mononeuropathies in adults. *Clinical Practice Guidelines of the Russian Federation*. 2024.
7. Guntinas-Lichius O. et al. Facial nerve electrodiagnostics in patients with facial palsy. 2020. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7286870/
8. Heo M.Y. et al. Combining five electrophysiological tests to predict outcomes in Bell's palsy. *European Archives of Oto-Rhino-Laryngology*. 2025. DOI: 10.1007/s00405-025-09419-4.

9. Woo S.H. et al. Prognostic value of electroneurography in severe facial palsy. *Annals of Rehabilitation Medicine*. 2023. DOI: 10.5535/arm.23082.
10. Gu C. et al. Prognostic value of the blink reflex in Bell's palsy. *Journal of Acupuncture and Rehabilitation*. 2024. DOI: 10.13045/jar.24.0034.
11. Tedeschi R. et al. Tools for diagnosing and quantifying facial palsy: a systematic review. *Acta Neurologica Belgica*. 2024;124:1805–1822. DOI: 10.1007/s13760-024-02630-w.
12. Mueller S.L.C. et al. Artificial intelligence in facial palsy management: systematic review and recommendations. *Plastic and Reconstructive Surgery*. 2025. DOI: 10.1097/PRS.0000000000012105.
13. Heinrich A. et al. Deep learning-based automated assessment of facial symmetry. *Scientific Reports*. 2025;15:31531. DOI: 10.1038/s41598-025-17172-1.
14. Teger Y. et al. Mobile application for facial function quantification using depth sensors. *JMIR mHealth and uHealth*. 2021;9(1):e19346. DOI: 10.2196/19346.
15. Mueller-Graff F.T. et al. Assessment and rehabilitation of facial palsy using mobile technology: pilot study. *JMIR Rehabilitation and Assistive Technologies*. 2026;13:e81963. DOI: 10.2196/81963.
16. Grillo M. et al. Remote rehabilitation for peripheral facial palsy: a scoping review. *Journal of Telemedicine and Telecare*. 2025. DOI: 10.1177/1357633X251342335.
17. Nakano H. et al. Physical therapy for peripheral facial palsy: a systematic review and meta-analysis. *Auris Nasus Larynx*. 2024;51(1):154–160.
18. Khan A.J. et al. Facial exercises for facial nerve palsy: an updated systematic review. *Clinical Rehabilitation*. 2022;36(11):1424–1449. DOI: 10.1177/02692155221110727.
19. Guntinas-Lichius O. et al. Management of post-facial palsy synkinesis: systematic evaluation and clinical guidelines. *Frontiers in Neurology*. 2022;13:1019554.
20. Hotton M. et al. Psychosocial impact of facial palsy: a systematic review. *British Journal of Health Psychology*. 2020;25(3):695–727. Available from: https://pubmed.ncbi.nlm.nih.gov/32538540/
21. Cuenca-Martínez F. et al. Anxiety, depression, and quality of life in peripheral facial palsy: a systematic review. *PeerJ*. 2020;8:e10449. DOI: 10.7717/peerj.10449.
22. Zavaliy L.B., Sinkin M.V., Petrikov S.S. et al. Diagnosis of facial nerve neuropathy in clinical practice: survey results of Russian neurologists. *Russian Neurological Journal*. 2023;28(2):15–24. DOI: 10.30629/2658-7947-2023-28-2-15-24.
23. Zavaliy L.B. et al. Rehabilitation of patients with facial neuropathy accompanied by hypertonia of contralateral facial muscles. *S.S. Korsakov Journal of Neurology and Psychiatry*. 2024;124(2):116–122. DOI: 10.17116/jnevro2024124021116.
24. Zavaliy L.B. et al. Comprehensive approach to diagnosis, treatment, and rehabilitation of facial nerve neuropathy. *Russian Neurological Journal*. 2022;27(1):69–79. DOI: 10.30629/2658-7947-2022-27-1-69-79.
25. Zavaliy L.B. et al. Botulinum toxin therapy in facial nerve neuropathy. *Russian Neurological Journal*. 2020;25(1):23–28. DOI: 10.30629/2658-7947-2020-25-1-23-28.
26. Savitskaya N.G., Suponeva N.A., Ostafiychuk A.V., Yankevich D.S. Electromyography in predicting recovery in idiopathic facial neuropathy. *Neuromuscular Diseases*. 2012;4:36–42.
27. Savitskaya N.G., Nikitin S.S., Illarioshkin S.N. et al. Recurrent facial nerve neuropathies: clinical, electrophysiological, and molecular analysis. *Annals of Clinical and Experimental Neurology*. 2011;5(4):29–32.
28. Petrikov S.S., Zavaliy L.B. et al. Neuroimaging in facial nerve neuropathy. *Russian Neurological Journal*. 2023;28(4):24–34. DOI: 10.30629/2658-7947-2023-28-4-24-34.
29. Petrikov S.S., Zavaliy L.B. et al. Patient routing, diagnosis, and treatment of adult facial neuropathy in a metropolis. *Russian Neurological Journal*. 2023;28(5):40–51.

30. Rakhmanina A.A., Kholmogorova A.B., Zavaliy L.B. Emotional maladjustment severity and emotion recognition ability in facial nerve dysfunction. *Experimental Psychology (Russia)*. 2024;17(4).
31. Akhrorova Sh.B. Age and gender clinical-pathogenetic features of acute facial nerve neuropathy. *International Neurological Journal*. 2017;4(90):52–56. DOI: 10.22141/2224-0713.4.90.2017.107262.
32. Sanoeva M.Zh., Rakhmatova D.I. Analysis of causal and hereditary factors predisposing to complicated facial neuropathy. *Journal of Neurology and Neurosurgical Research*. 2021;2(2).
33. Asadova N.S., Djurabekova A.T., Utaganova G.Kh. et al. Clinical features of pediatric facial nerve neuropathy in the acute period. *Achievements of Science and Education*. 2019;13(54).
34. Asadova N.S., Djurabekova A.T., Utaganova G.Kh. Clinical and electromyographic prognosis of facial nerve neuropathy in children. *Doctor Ahborotnomasi*. 2021;1(98):6–9. DOI: 10.38095/2181-466x-2021981-6-9.
35. Safarova M.S. Improvement of comprehensive treatment methods for facial neuritis. *Integrative Dentistry and Maxillofacial Surgery*. 2023;2(2):118–122. DOI: 10.57231/j.idmfs.2023.2.2.017.
36. Kamoldinova D.B., Kobilov Sh.M., Nazarova G.T. Early correction of facial nerve neuropathy in children. *Economy and Society*. 2022.
37. Shamalov N.A., Zavaliy L.B., Petrikov S.S. et al. Epidemiology of facial nerve disorders in a metropolis according to unified health information system data. *Medicine and Healthcare Organization*. 2024;9(2):60–69. DOI: 10.56871/MHC0.2024.64.49.007.
38. Mengi E., Kara K.O., Ardıc F.N. et al. Reliability comparison of House-Brackmann scale, Facial Nerve Grading System 2.0, and Sunnybrook scale. *International Journal of Advanced Otology*. 2024;20(1):14–18. DOI: 10.5152/iao.2024.231162.
39. House J.W., Brackmann D.E. Facial nerve grading system. *Otolaryngology–Head and Neck Surgery*. 1985;93(2):146–147.